The key is for drugmakers to work with the intent of outpacing the spread of the drug-resistant strains of the infection to stay ahead of consequences, which could entail getting set “back to the pre-antibiotic era,” Jeffrey Klausner, MD, a professor of medicine and public health at the University of Southern California told Bloomberg.
Gonorrhea specifically is more prone to becoming drug-resistant than other sexually transmitted infections because as cases have gone up in recent years after a long stretch of falling, “a rise in overall infections gives it more chances to adapt,” according to Bloomberg.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
